Preclinical CRO – Medicilon
Medicilon-Preclinical CRO：
Medicilon (stock code: 688202. SH) is a drug research and development outsourcing service company (CRO). Pharmacology, pharmacokinetics, and toxicology evaluation are comprehensive technical service platforms that meet international standards. Medicilon is one of the internationalized companies in China’s local CRO. In 2008, it cooperated with MPI Research of the United States to establish an animal experiment company. The animal experiment facilities have obtained the International Laboratory Animal Assessment and Accreditation (AAALAC) and China Food and Drug Administration GLP certificates. We have reached the US Food and Drug Administration GLP standards. Medicilon will help customers achieve their goals faster with efficient and cost-effective one-stop professional services.
CRO companies mainly provide pharmaceutical outsourcing services for pharmaceutical companies, pharmaceutical factories, schools, and other institutions. They started relatively late in China but developed rapidly.
New drug research and development contract outsourcing service (Contract Research Organization, CRO) emerged in the United States in the 1970s, developed rapidly in the United States, Europe, and Japan in the late 1980s, and became a vital link in the pharmaceutical industry chain in the 1990s. After decades of development, CRO has become a relatively complete technical service industry system. The specialized services that can be provided include drug product development, preclinical trials and clinical trials, data management, drug applications, etc., covering almost all aspects of drug research and development.
By the middle of 2022, Medicilon, a preclinical CRO, has provided new drug R&D services to more than 1,710 customers worldwide and participated in the R&D of 268 IND-approved new drug projects, growing together with high-quality customers at home and abroad. Medicilon will continue to base itself on a global perspective, focus on innovation in China, and contribute to human health!
Listed for 3 consecutive years! Medicilon won the “Top 20 Chinese R&D CRO Enterprises in 2022”
On December 9, 2022, the “2022 High-Quality Development Conference of the Great Health Industry and the 7th China Pharmaceutical R&D Innovation Summit” jointly organized by Yaozhi.com and China Pharmaceutical Industry Journal Publisher was successfully held online.
On July 12, the 2021 “Top 20 CXO (including CDMO) Enterprise in China” selected by Menet was officially released, which once again demonstrated the professionalism and influence of a strong enterprises in China’s pharmaceutical industries.
Medicilon was Awarded The “Golden Horse Award-2021 Best Preclinical CRO/CDMO Enterprise”
From October 19-21, 2021, a grand event that has attracted the attention of the national pharmaceutical industry, “2021 Nanjing International Summit on Innovation and Investment in Novel Medicine, Life and Health” was successfully held in Nanjing, China.
The future development trend of my country’s preclinical CRO industry:
The first is the integration of outsourcing services. CRO outsourcing services can cover the entire pharmaceutical research and development stage worldwide. From new drug research and development to new drug launches, large multinational CRO companies can provide comprehensive one-stop services. The overall CRO industry in my country has just started, and the industrial scale has excellent potential for development. For local CRO companies, building a complete industrial service chain in the future can not only improve the technological innovation capability of my country’s pharmaceutical industry, push my country to enter the upstream of the pharmaceutical industry value chain as soon as possible, but also meet the growing demand of my country’s pharmaceutical market. The inevitable result of the general trend.
The second is the internationalization of qualification certification standards.As an essential link in the value chain of the global pharmaceutical industry, CROs must inevitably be in line with international standards in terms of the standard quality system. After the establishment of SFDA, China vigorously promoted the establishment of standard quality systems such as GMP, GCP, and GLP and gradually moved closer to the normal quality systems of Western developed countries. But it is undeniable that compared with the strict quality systems of western developed countries, especially the United States, there is still a long distance between China and them. For the outsourcing business of new drug research and development in the true sense, how to meet the standards of Western countries in terms of quality standards (such as the GLP standard of the US FDA) will also be a necessary condition for the future development of local CRO companies.
The third is advanced R&D operation technology and service management process. It is mainly manifested in the fact that CRO enterprises strengthen professional drug discovery technology and establish a research and development model in line with the development of new technologies represented by biotechnology. And for the timeliness requirement, build the network tool EDC, strengthen the relationship with the test site, and accelerate the clinical trial process.
Fourth, technological innovation and expansion have become the focus of corporate competition. CRO business is expanding to a broader range of fields beyond clinical trials, and CROs in some developed countries have extended their services to drug research and development, preclinical research, pharmacoeconomics, pharmacogenomics, drug safety evaluation, phase I-IV Clinical trials, trial design, selection of investigators and trial units, monitoring, auditing, data management and analysis, informatics, clinical documents, policy and regulation consulting, product registration, production and packaging, promotion, marketing, product release and sales support And various related business consulting and many other fields. How to enable local CRO companies to have the technical expertise and globalization, high-quality technology development, and clinical trial management capabilities required by pharmaceutical companies to meet the new drug launch needs of these large pharmaceutical companies will also be the goal of future development.
Finally, the structural adjustment of the CRO industry is accelerating. With my country’s accession to the WTO and the acceleration of economic globalization, large multinational CRO companies have spotted the development prospects of my country’s pharmaceutical market and the advantages of R&D costs and entered the country aggressively, and established CRO companies with foreign backgrounds in my country in the form of a sole proprietorship, joint ventures, and cooperation. With the continuous growth of the CRO industry in the future, the competition will inevitably tend to be internationalized. How local enterprises can effectively cooperate with multinational enterprises, digest and absorb advanced technologies, form their unique technological advantages, and adapt to the new competitive environment will be an essential issue before them.
